{"success":true,"data":{"pressRelease":{"id":"71997","rtpr_id":"nPn9wYtvwa","ticker":"ABT","exchange":"NYSE","all_tickers":["ABT"],"title":"ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing","author":"PR Newswire","published_at":"2026-06-24T12:30:00.259Z","article_body":"ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing\n\nPR Newswire\n\nCARLSBAD, Calif., June 24, 2026\n\nALZpath Strengthens Market Leadership with Abbott Agreement to Help Enable\nEarly Alzheimer's Diagnosis at Global Scale\n\nCARLSBAD, Calif., June 24, 2026 /PRNewswire/ -- ALZpath Inc.,\n(https://alzpath.bio/)  the leader in blood test-based diagnostic solutions\nfor Alzheimer's disease, today announced a licensing agreement with Abbott\n(NYSE: ABT), a global healthcare leader, to incorporate ALZpath's proprietary\nphosphorylated Tau 217 (pTau217) antibody into the development of an in vitro\ndiagnostic (IVD) test for Alzheimer's disease. The test would be designed for\nuse on Abbott's Alinity ci-series systems, which represents one of the largest\ninstall bases of immunoassay instruments worldwide.\n\nALZpath's pTau217 antibody is among the most clinically validated for\ndetecting Alzheimer's disease pathology. Backed by more than 200 peer-reviewed\npublications across 18 countries, the antibody demonstrates high accuracy and\nsensitivity in identifying Alzheimer's disease biology.\n\n\"This agreement further strengthens ALZpath's leadership in blood-based\nAlzheimer's testing and reinforces our position as the foundational component\nsupporting the overwhelming majority of the pTau217 IVD market,\" said Mike\nBanville, CEO of ALZpath. \"As blood-based biomarkers become central to how\nAlzheimer's disease is detected and managed, partnering with a global\nhealthcare leader like Abbott can enable high-performance testing to reach\nclinicians and patients around the world at scale. Together with our\ndiagnostic partners, we remain focused on bringing our highly accurate and\nsensitive antibody into routine care, including primary care, to reach\npatients in need.\"\n\nAs disease-modifying therapies continue to expand, accessible diagnostics are\nessential for earlier patient identification. ALZpath's pTau217 antibody\noffers a scalable alternative to PET imaging and cerebrospinal fluid (CSF)\nanalysis, which are costly, invasive, and difficult to deploy at scale.\nBlood-based biomarkers may also play a role in monitoring disease progression\nand treatment response in routine clinical practice.\n\n\"Abbott has spent more than a decade advancing brain health science to give\nclinicians earlier, clearer answers,\" said John Frels, vice president of\nresearch and development in Abbott's Core Diagnostics business. \"Our work –\nincluding pioneering the first FDA cleared rapid blood test that helps assess\nmild traumatic brain injuries by providing objective biomarker data – shows\nwhat's possible when we deepen our understanding of the brain. Collaborations\nlike this are accelerating the next era of Alzheimer's disease research,\nclinical trials for therapies and ultimately patient care.\"\n\nAbout ALZpath\n\nALZpath, Inc. is a leader in blood test-based diagnostic solutions for\nAlzheimer's disease. Its proprietary pTau217 antibody, used in many of the\nmost advanced and widely available blood-based tests, is helping transform how\nAlzheimer's disease is detected, treated, and monitored. Through licensing\nagreements with global industry leaders along with collaborations with\nworld-class laboratories, ALZpath is expanding access to earlier, more\nscalable detection. ALZpath's innovations have earned multiple honors,\nincluding Time Magazine Best Inventions (2024), Fast Company Most Innovative\nCompanies (2025), and BioTech Breakthrough \"Diagnostic Innovation of the Year\"\n(2025). To learn more, visit https://alzpath.bio/\n(https://urldefense.com/v3/__https:/alzpath.bio/__;!!DlCMXiNAtWOc!w3jgFcWFDAwYMsdCYfAEsXHvg8gcetYSxAmfgZla0-3Ecj8aPBFrIO3z-z47N_P_9XThulN7wsqSjVZdhpnA$)\n and follow ALZpath on LinkedIn\n(https://urldefense.com/v3/__https:/www.linkedin.com/company/alzpath-inc/?viewAsMember=true__;!!DlCMXiNAtWOc!w3jgFcWFDAwYMsdCYfAEsXHvg8gcetYSxAmfgZla0-3Ecj8aPBFrIO3z-z47N_P_9XThulN7wsqSjTR1gRRE$)\n, X (https://x.com/AlZpath) , BlueSky\n(https://bsky.app/profile/alzpath.bsky.social) , and Facebook\n(https://www.facebook.com/alzpathinc/) .\n\nALZpath Media Contact:\nJessica Hoffman\nFINN Partners\nJessica.hoffman@finnpartners.com (mailto:Jessica.hoffman@finnpartners.com)\n\n \n\nView original\ncontent:https://www.prnewswire.com/news-releases/alzpath-signs-global-licensing-agreement-with-abbott-to-advance-blood-based-alzheimers-disease-testing-302808974.html\n(https://www.prnewswire.com/news-releases/alzpath-signs-global-licensing-agreement-with-abbott-to-advance-blood-based-alzheimers-disease-testing-302808974.html)\n\nSOURCE ALZpath, Inc.\n\n\n\n929 588 2012\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn9wYtvwa","title":"ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing","author":"PR Newswire","ticker":"ABT","created":"2026-06-24T12:30:00.259Z","tickers":["ABT"],"exchange":"NYSE","article_body":"ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing\n\nPR Newswire\n\nCARLSBAD, Calif., June 24, 2026\n\nALZpath Strengthens Market Leadership with Abbott Agreement to Help Enable\nEarly Alzheimer's Diagnosis at Global Scale\n\nCARLSBAD, Calif., June 24, 2026 /PRNewswire/ -- ALZpath Inc.,\n(https://alzpath.bio/)  the leader in blood test-based diagnostic solutions\nfor Alzheimer's disease, today announced a licensing agreement with Abbott\n(NYSE: ABT), a global healthcare leader, to incorporate ALZpath's proprietary\nphosphorylated Tau 217 (pTau217) antibody into the development of an in vitro\ndiagnostic (IVD) test for Alzheimer's disease. The test would be designed for\nuse on Abbott's Alinity ci-series systems, which represents one of the largest\ninstall bases of immunoassay instruments worldwide.\n\nALZpath's pTau217 antibody is among the most clinically validated for\ndetecting Alzheimer's disease pathology. Backed by more than 200 peer-reviewed\npublications across 18 countries, the antibody demonstrates high accuracy and\nsensitivity in identifying Alzheimer's disease biology.\n\n\"This agreement further strengthens ALZpath's leadership in blood-based\nAlzheimer's testing and reinforces our position as the foundational component\nsupporting the overwhelming majority of the pTau217 IVD market,\" said Mike\nBanville, CEO of ALZpath. \"As blood-based biomarkers become central to how\nAlzheimer's disease is detected and managed, partnering with a global\nhealthcare leader like Abbott can enable high-performance testing to reach\nclinicians and patients around the world at scale. Together with our\ndiagnostic partners, we remain focused on bringing our highly accurate and\nsensitive antibody into routine care, including primary care, to reach\npatients in need.\"\n\nAs disease-modifying therapies continue to expand, accessible diagnostics are\nessential for earlier patient identification. ALZpath's pTau217 antibody\noffers a scalable alternative to PET imaging and cerebrospinal fluid (CSF)\nanalysis, which are costly, invasive, and difficult to deploy at scale.\nBlood-based biomarkers may also play a role in monitoring disease progression\nand treatment response in routine clinical practice.\n\n\"Abbott has spent more than a decade advancing brain health science to give\nclinicians earlier, clearer answers,\" said John Frels, vice president of\nresearch and development in Abbott's Core Diagnostics business. \"Our work –\nincluding pioneering the first FDA cleared rapid blood test that helps assess\nmild traumatic brain injuries by providing objective biomarker data – shows\nwhat's possible when we deepen our understanding of the brain. Collaborations\nlike this are accelerating the next era of Alzheimer's disease research,\nclinical trials for therapies and ultimately patient care.\"\n\nAbout ALZpath\n\nALZpath, Inc. is a leader in blood test-based diagnostic solutions for\nAlzheimer's disease. Its proprietary pTau217 antibody, used in many of the\nmost advanced and widely available blood-based tests, is helping transform how\nAlzheimer's disease is detected, treated, and monitored. Through licensing\nagreements with global industry leaders along with collaborations with\nworld-class laboratories, ALZpath is expanding access to earlier, more\nscalable detection. ALZpath's innovations have earned multiple honors,\nincluding Time Magazine Best Inventions (2024), Fast Company Most Innovative\nCompanies (2025), and BioTech Breakthrough \"Diagnostic Innovation of the Year\"\n(2025). To learn more, visit https://alzpath.bio/\n(https://urldefense.com/v3/__https:/alzpath.bio/__;!!DlCMXiNAtWOc!w3jgFcWFDAwYMsdCYfAEsXHvg8gcetYSxAmfgZla0-3Ecj8aPBFrIO3z-z47N_P_9XThulN7wsqSjVZdhpnA$)\n and follow ALZpath on LinkedIn\n(https://urldefense.com/v3/__https:/www.linkedin.com/company/alzpath-inc/?viewAsMember=true__;!!DlCMXiNAtWOc!w3jgFcWFDAwYMsdCYfAEsXHvg8gcetYSxAmfgZla0-3Ecj8aPBFrIO3z-z47N_P_9XThulN7wsqSjTR1gRRE$)\n, X (https://x.com/AlZpath) , BlueSky\n(https://bsky.app/profile/alzpath.bsky.social) , and Facebook\n(https://www.facebook.com/alzpathinc/) .\n\nALZpath Media Contact:\nJessica Hoffman\nFINN Partners\nJessica.hoffman@finnpartners.com (mailto:Jessica.hoffman@finnpartners.com)\n\n \n\nView original\ncontent:https://www.prnewswire.com/news-releases/alzpath-signs-global-licensing-agreement-with-abbott-to-advance-blood-based-alzheimers-disease-testing-302808974.html\n(https://www.prnewswire.com/news-releases/alzpath-signs-global-licensing-agreement-with-abbott-to-advance-blood-based-alzheimers-disease-testing-302808974.html)\n\nSOURCE ALZpath, Inc.\n\n\n\n929 588 2012\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-06-24T12:30:00.464912304Z","server_sent_at_ms":1782304200464},"received_at":"2026-06-24T12:30:00.678Z","source_url":"https://www.prnewswire.com/news-releases/alzpath-signs-global-licensing-agreement-with-abbott-to-advance-blood-based-alzheimers-disease-testing-302808974.html"},"analysis":{"id":"61371","press_release_id":"71997","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"partnership","narrative":"Abbott signed a global licensing agreement with ALZpath to incorporate ALZpath's proprietary pTau217 antibody into the development of an in vitro diagnostic test for Alzheimer's disease on Abbott's Alinity ci-series systems.\n\nThe antibody is backed by more than 200 peer-reviewed publications across 18 countries and offers a scalable alternative to PET imaging and cerebrospinal fluid analysis.\n\nThis partnership aims to leverage Abbott's large instrument install base to expand access to early Alzheimer's diagnostics globally.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Abbott secures rights to leading Alzheimer's biomarker to enhance its diagnostic platform capabilities."},"keyFigures":{"customDimensions":{"countries":18,"peer_reviewed_publications":"more than 200"}},"quotedText":"Collaborations like this are accelerating the next era of Alzheimer's disease research, clinical trials for therapies and ultimately patient care.","namedEntities":{"people":[{"name":"Mike Banville","role":"CEO of ALZpath"},{"name":"John Frels","role":"Vice President of Research and Development, Abbott Core Diagnostics"}],"products":["phosphorylated Tau 217 (pTau217) antibody","Alinity ci-series systems"],"companies":[{"name":"Abbott","ticker":"ABT"},{"name":"ALZpath Inc."}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Strategic licensing agreement strengthens Abbott's diagnostics portfolio by integrating a validated Alzheimer's biomarker into its high-volume Alinity systems, though no financial terms were disclosed."},"tickerRelevance":{"others":[],"primary":"ABT"},"globalImportance":30,"audienceRelevance":50,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mega-cap","eventGravity":"partnership_deal","sectorWeight":"high"}},"event_type":"partnership","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Abbott signed a global licensing agreement with ALZpath to incorporate ALZpath's proprietary pTau217 antibody into the development of an in vitro diagnostic test for Alzheimer's disease on Abbott's Alinity ci-series systems.\n\nThe antibody is backed by more than 200 peer-reviewed publications across 18 countries and offers a scalable alternative to PET imaging and cerebrospinal fluid analysis.\n\nThis partnership aims to leverage Abbott's large instrument install base to expand access to early Alzheimer's diagnostics globally.","key_figures":{"customDimensions":{"countries":18,"peer_reviewed_publications":"more than 200"}},"named_entities":{"people":[{"name":"Mike Banville","role":"CEO of ALZpath"},{"name":"John Frels","role":"Vice President of Research and Development, Abbott Core Diagnostics"}],"products":["phosphorylated Tau 217 (pTau217) antibody","Alinity ci-series systems"],"companies":[{"name":"Abbott","ticker":"ABT"},{"name":"ALZpath Inc."}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-24T12:50:16.965Z","global_importance":30,"audience_relevance":50,"importance_components":{"tickerTier":"mega-cap","eventGravity":"partnership_deal","sectorWeight":"high"}},"durationMs":null,"modelName":"george-droid-qwen-72b"}}